Asthma & COPD
The primary purpose of InflammoGen is to continue to develop
BCP-1071 and BCP-1081, which are novel, non-steroid polypeptide
drugs. BCP-1071 has shown compelling results in two animal
(mammalian) species and is being developed and designed
to address chronic inflammatory diseases, such as asthma and
COPD.
In stark contrast to current treatments, which merely
focus on individual symptoms or a single disease state,
BCP-1071 has shown potent anti-inflammatory effects at all
levels, while completely restoring normal lung physiology
and function. BCP-1071 has been identified as the most efficient
molecule for pulmonary drug delivery in humans. Moreover,
its safety and tolerability in humans are well-established.
|
